JP Morgan Chase
IKT icon

JP Morgan Chase’s Inhibikase Therapeutics IKT Stock Holding History

JP Morgan Chase’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$519K Buy
328,518
+303,669
+1,222% +$539K ﹤0.01% 4978
2025
Q4 		$50.9K Sell
24,849
-25,088
-50% -$39.9K ﹤0.01% 6218
2025
Q3 		$80.9K Buy
49,937
+21,358
+75% +$37K ﹤0.01% 6023
2025
Q2 		$55.7K Buy
+28,579
New +$56K ﹤0.01% 5880
2023
Q4 		– Sell
-5
Closed -$7 – 7679
2023
Q3 		$7 Buy
5
+3
+150% +$7 ﹤0.01% 7331
2023
Q2 		$7 Buy
+2
New +$7 ﹤0.01% 6828

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase's IKT Position: Q1 2026 in Review

JP Morgan Chase increased its Inhibikase Therapeutics (IKT) stake by 1,222% in Q1 2026, buying an estimated $539K and bringing the position to 328,518 shares worth $519K. The position accounts for ﹤0.01% of the portfolio, ranked #4978.

JP Morgan Chase first reported a position in IKT in Q2 2023 and has held it in 6 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • JP Morgan Chase held 328,518 shares of Inhibikase Therapeutics worth $519K as of Q1 2026.
  • JP Morgan Chase bought 303,669 Inhibikase Therapeutics shares in Q1 2026, an estimated $539K.
  • Inhibikase Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4978 holding.
  • JP Morgan Chase first reported a position in Inhibikase Therapeutics in Q2 2023 and has held it in 6 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.